secwatch / observer
8-K filed May 28, 2026, 8:18 AM ET ticker ANRO CIK 0001999480
leadership confidence high sentiment neutral materiality 0.50

Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president

Alto Neuroscience, Inc.

item 5.02

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001999480-26-000016
form_type
8-K
ticker
ANRO
cik
0001999480
company_name
Alto Neuroscience, Inc.
filed_at
2026-05-28T12:18:14+00:00
discovered_at
2026-05-28T12:20:00.305607+00:00
generated_at
2026-05-28T12:20:17.492172+00:00
sec_items
["5.02"]
event_type
leadership
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001999480-26-000016
json_url
https://secwatch.observer/filing/0001999480-26-000016.json
markdown_url
https://secwatch.observer/filing/0001999480-26-000016.md
text_url
https://secwatch.observer/filing/0001999480-26-000016.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/0001999480-26-000016-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/alto-20260527.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Miller

Director
ANRO · Alto Neuroscience, Inc.
Effective
2026-05-27
Filed
May 28, 2026, 8:18 AM ET
the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Source-grounded claims

c5d0d5e62f

Andrew Miller was appointed as Director at Alto Neuroscience, Inc..

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

Federal Home Loan Bank of Pittsburgh

FHLB Pittsburgh CFO Edward V. Weller to retire on Oct 20, 2026

Federal Home Loan Bank of Pittsburgh June 1, 2026, 3:08 PM ET leadership Items 5.02

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

On May 28, 2026, the Federal Home Loan Bank of Pittsburgh (Bank) received notice from Edward V. Weller, Chief Financial Officer, of his intent to retire from the Bank on or about October 20, 2026.

Filing page SEC filing

MGNO

Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair

Magnolia Bancorp, Inc. June 1, 2026, 2:15 PM ET leadership Items 5.02, 5.07, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.

Filing page SEC filing

FSBW

FS Bancorp names Matt Mullet CEO as planned; Joe Adams retires but stays on board

FS Bancorp, Inc. June 1, 2026, 11:31 AM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

it has named Matthew D. Mullet as Chief Executive Officer of the Company effective June 1, 2026

Filing page SEC filing

RVRC

Revium Rx CFO Arie Gordashnikov resigns; Igor Bluvstein appointed effective May 27, 2026

Revium Rx. June 1, 2026, 9:58 AM ET leadership Items 5.02

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

On May 27, 2026, our Board of Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.

Filing page SEC filing

MED

Medifast Chief Legal Officer resigns; receives one-month severance of $35,648

MEDIFAST INC June 1, 2026, 8:59 AM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

Effective as of May 29, 2026, Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc. (the “Company”), tendered his resignation from the Company.

Filing page SEC filing

FUSE

Fusemachines appoints AI pioneer Dr. Julia Hirschberg to board; Shrestha resigns

Fusemachines Inc. June 1, 2026, 8:18 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

Effective May 31, 2026, the board of directors (the “Board”) of Fusemachines Inc., a Delaware corporation (the “Company” or “Fusemachines”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Julia Hirschberg as a member of the Board as a Class II director, until the Company’s 2027 annual meeting of stockholders or until Ms. Hirschberg’s successor is duly elected and qualified.

Filing page SEC filing

CG

Carlyle appoints Kate Heinzelman as General Counsel; Jeff Ferguson to be Senior Advisor

Carlyle Group Inc. June 1, 2026, 8:00 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

Mr. Ferguson will become a Senior Advisor to Carlyle

Filing page SEC filing

ATH-PA

Athene appoints Matthew Michelini as President effective July 1, 2026

Athene Holding Ltd. June 1, 2026, 7:36 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.

Comparable filing

On June 1, 2026, Athene Holding Ltd. (the “Company”) appointed Matthew Michelini President of the Company, with such appointment to be effective as of July 1, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001999480-26-000016
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.